Allergan plc (AGN)
(Delayed Data from NYSE)
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Intercept (ICPT) Stock Loses Sheen in 2017: What Lies Ahead?
by Zacks Equity Research
Intercept (ICPT) had a tough time in 2017 after news of death were out related to lead drug's Ocaliva's dosing. We do not expect a phenomenal revival in 2018 either.
Allergan/Paratek's Acne Candidate NDA Filing Accepted by FDA
by Zacks Equity Research
Allergan (AGN) and partner Paratek announces that its new drug application for Seysara has been accepted for review by the FDA for moderate to severe acne vulgaris.
Allergan's Vraylar Positive for Bipolar Disease in Phase III
by Zacks Equity Research
Allergan (AGN) releases positive top-line results from a phase III study on Vraylar for treatment of bipolar I depression. The trial meets its primary endpoints with significant progress in patients.
Teva's Migraine Candidate Gets Priority Review From FDA
by Zacks Equity Research
Teva's (TEVA) biologics license application (BLA) seeking approval for fremanezumab as a preventive treatment for migraine gets priority review from FDA
Aerie (AERI) Gets Early FDA Approval for Lead Drug Rhopressa
by Zacks Equity Research
Aerie (AERI) got a significant boost with the FDA approving its lead drug Rhopressa for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, ahead of schedule.
Allergan Inks Deal to Buy Texas-Based Repros Therapeutics
by Zacks Equity Research
Allergan (AGN) signs a definitive contract to acquire Texas-based Repros Therapeutics, which is focused on developing new drugs to treat hormonal and reproductive system disorders.
3 Drug/Biotech Stocks Up More Than 10% This Week
by Zacks Equity Research
The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.
Roche Reports Positive Data from Tecentriq Combination Study
by Zacks Equity Research
Roche reported positive data from a combination study of Tecentriq and Avastin in metastatic renal cell carcinoma patients.
3 Drug/Biotech Stocks Up More Than 10% This Week
by Zacks Equity Research
The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.
Roche's Avastin Gets Full FDA Approval for Brain Cancer
by Zacks Equity Research
Roche (RHHBY) announced that the FDA converted accelerated approval for Avastin to full approval for the patients previously treated for aggressive form of brain cancer.
Revance's Neuromodulator Injection Positive in Phase III
by Zacks Equity Research
Revance (RVNC) releases positive top-line data from two pivotal phase III trials, evaluating RT002 for reducing wrinkles between the brows. The studies meet both primary and secondary endpoints.
Here's Why Sarepta Stock is Up More Than 70% in 6 Months
by Zacks Equity Research
Sarepta's (SRPT) key product, Exondys 51, and lead pipeline candidate, golodirsen, have put up a good show in the past six months.
AstraZeneca's COPD Drug Succeeds in Label Expansion Study
by Zacks Equity Research
AstraZeneca (AZN) releases positive top-line data from a phase IV study, evaluating label expansion of Tudorza for chronic obstructive pulmonary disease with cardiovascular risk factors.
Ironwood Succeeds in Diabetic Hypertension Phase II Study
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) pipeline candidate, IW-1973, reduces blood pressure and improves metabolic parameters in type II diabetes with hypertension patients in a phase IIa study.
Teva's New CEO Re-Shuffles Senior Management, Stock Up 7%
by Zacks Equity Research
Teva (TEVA) announced several organizational changes in order to save costs and improve productivity.
Teva (TEVA) Stock Rises 5% on Reports of Massive Job Cuts
by Zacks Equity Research
Per an Israeli news release, Teva (TEVA) is expected to lay off 4000 employees
Allergan's Vraylar Gets FDA Nod for Maintenance Therapy
by Zacks Equity Research
Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.
Amgen Gets Positive CHMP Opinion to Expand Nplate's Label
by Zacks Equity Research
Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.
Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Increased operating expenses mar Aerie's (AERI) Q3 performance.
Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND
by Zacks Equity Research
The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if some small biotechs, due to report on Nov 9, follow suit.
Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the third quarter. Demand for Linzess rises.
Teva (TEVA) Stock Plunges 20% on Q3 Earnings Miss & View Cut
by Zacks Equity Research
Teva's (TEVA) third-quarter earnings missed estimates while revenues were in line. The company lowered its earnings and revenue guidance for 2017, for the second time this year.
Key Predictions for Q3 Earnings Reports of MYL, HZNP & KERX
by Zacks Equity Research
The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if generic maker Mylan and other small companies follow suit.
Allergan (AGN) Tops Q3 Earnings Estimates, Tweaks 2017 View
by Zacks Equity Research
Allergan (AGN) beat expectations for earnings while delivering in-line revenues in Q3. While the company slightly lowered its sales guidance, it raised the upper end of the earnings guidance.
Allergan (AGN) Beats Q3 Earnings, Sales In Line, Stock Up
by Zacks Equity Research
Allergan plc (AGN) beat expectations for earnings while delivering in-line revenues in Q3. Revenues rose 11.4% year over year.